Account
Watchlists
Bookmarks
Pricing
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
No. of Analysts
1Y Price Target
Q3 EPS Estimate
Q3 Revenue Estimate
Price, EPS and Revenue Projections
Strong Buy
2
Buy
4
Hold
1
Sell
0
Strong Sell
0
updated on
Dec 03, 2025
Bearish
3
Neutral
9
Bullish
2
Bearish
22
Neutral
9
Bullish
15
Bearish
19
Neutral
0
Bullish
13
Market Cap
₹ 5,821 Cr
P/E
31.92
Get In-depth insights on EPS and Revenue forecasts
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
760.85 | 6,852 Cr | 28.58 | 3.35 | 0.66 | 11.72 | 12.99 | 7.34 | |
422.50 | 6,852 Cr | 30.39 | 2.82 | 1.19 | 9.27 | 12.51 | 7.81 | |
422.30 | 6,652 Cr | 21.63 | 2.11 | 0.00 | 10.07 | 8.99 | 6.27 | |
723.30 | 5,821 Cr | 31.92 | 5.38 | 0.14 | 16.86 | 22.47 | 15.16 | |
210.40 | 5,354 Cr | 122.50 | 6.61 | 0.00 | 5.17 | 10.38 | 3.13 | |
1687.00 | 5,211 Cr | — | 15.87 | 0.05 | -19.58 | -9.69 | -10.20 | |
822.85 | 4,173 Cr | 79.88 | 3.28 | 0.00 | 4.10 | 4.28 | 3.02 |
Supriya Lifescience Limited is a major Indian manufacturer specializing in active pharmaceutical ingredients (APIs), with a robust focus on export markets. The company deals with over 39 APIs across various therapeutic segments like antihistamines, anesthetics, vitamins, anti-asthmatics, and anti-allergics.
The company is capitalizing on significant growth, achieving a 20% year-over-year revenue increase in Q2 FY26. Notably, exports remain their business cornerstone, accounting for 81% of revenue, highlighting their global outreach.
Supriya Lifescience has a strong market position supported by state-of-the-art manufacturing facilities and advanced R&D capabilities, allowing backward integration for 79% of its Q2 FY26 revenues. This provides operational and cost efficiencies.
The company is on track to reach INR 1,000 crore revenue by Financial Year 2027, supported by a pipeline of 3-4 product launches annually and expansion into anesthetics, anti-diabetics, anti-anxiety, vitamins, and ADHD treatment markets.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
5,821 Cr
High Risk
31.9
30.8
1.4
5.4
841.70
556.85
Sales CAGR
1Y
22.12%
3Y
9.93%
5Y
16.81%
10Y
17.28%
Profit CAGR
1Y
57.80%
3Y
7.38%
5Y
20.71%
10Y
47.48%
ROE
TTM
16.86%
3Y
15.80%
5Y
19.80%
10Y
21.30%
ROCE
TTM
22.47%
3Y
20.95%
5Y
26.25%
10Y
28.24%
Performance
STEADY PERFORMER
Valuation
REASONABLE
Growth
STABLE
Profitability
HIGH MARGIN
Technicals
Bearish
Risk
MODERATE RISK
Turned 1 L into 3.05 L in last 3 Years
